In our assays, nintedanib, one of two currently approved drugs for IPF, inhibited TGF–β1–induced myofibroblast formation in the HCA, inhibited impedance changes, and attenuated α–SMA and COL1 increase in IPQA (Table 3). The gene discussed is ACTA1; the disease is idiopathic pulmonary fibrosis.